Monitor LEXX's stock price after the August 3 effective date to see if it sustains above $1.00. If the price fails to hold, delisting risk remains and could trigger further volatility. The split itself does not improve business fundamentals.
Price Chart
Executive Summary
Lexaria Bioscience Corp. filed an 8-K announcing a 1-for-15 reverse stock split effective August 3, 2026, to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The split reduces outstanding shares from 24,787,446 to approximately 1,652,518 and authorized shares from 220,000,000 to 14,666,667. No fractional shares will be issued; fractional interests are rounded up. The action is a routine corporate measure to avoid delisting and does not alter proportional ownership.
Key Facts
- 1-for-15 reverse stock split effective August 3, 2026
- Outstanding shares reduced from 24,787,446 to ~1,652,518
- Authorized shares reduced from 220,000,000 to 14,666,667
- No fractional shares; rounding up to whole shares
- Primary goal: regain compliance with Nasdaq Listing Rule 5550(a)(2) minimum $1.00 bid price
- No stockholder approval required under Nevada law
- Company anticipates requesting a Nasdaq hearing if needed but expects to comply by mid-August
Financial Impact
No direct financial impact; the reverse split is a mechanical share consolidation that does not change the company's market capitalization or fundamentals.
Risk Factors
- Failure to maintain Nasdaq minimum bid price post-split could lead to delisting
- Reverse splits often signal underlying stock weakness and can deter retail investors
- Potential future dilution if the company needs to raise capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001640334-26-001258 |
| Document: lxrp_ex991.htm | 0001640334-26-001258 |
| Document: 0001640334-26-001258-index-headers.html | 0001640334-26-001258 |
| Document: 0001640334-26-001258-index.html | 0001640334-26-001258 |
| Document: 0001640334-26-001258.txt | 0001640334-26-001258 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | EFFECT | $2.82 $2.99 | ▼ −6.03% | ▼ −5.74% | $3.12 (−10.64%) |
Oct 1, 2026 25d ago | S-3 | $2.88 $2.77 | ▲ +3.82% | ▲ +4.49% | $3.12 (−8.33%) |
Sep 1, 2026 8w ago | 8-K | $12.48 $13.21 | ▲ +5.85% | ▲ +5.41% | $3.12 (−74.99%) |
Aug 10, 2026 11w ago | 8-K | $5.79 $6.12 | ▼ −5.70% | ▼ −5.45% | $3.12 (+46.11%) |
Jul 30, 2026 12w ago | 8-K | $0.3963 $0.3910 | ▼ −1.34% | ▼ −2.06% | $3.12 (+687.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers